Home/Filings/4/0000904454-16-001502
4//SEC Filing

OBALON THERAPEUTICS INC 4

Accession 0000904454-16-001502

$HINDCIK 0001427570operating

Filed

Oct 13, 8:00 PM ET

Accepted

Oct 14, 12:04 PM ET

Size

18.7 KB

Accession

0000904454-16-001502

Insider Transaction Report

Form 4
Period: 2016-10-12
Transactions
  • Conversion

    Series A Preferred Stock

    2016-10-1211,0830 total
    Common Stock (14,716 underlying)
  • Conversion

    Common Stock

    2016-10-12+49,57049,570 total
  • Conversion

    Series B Preferred Stock

    2016-10-1220,5830 total
    Common Stock (20,583 underlying)
  • Conversion

    Series C Preferred Stock

    2016-10-1214,2710 total
    Common Stock (14,271 underlying)
DOVEY BRIAN H
10% Owner
Transactions
  • Conversion

    Series A Preferred Stock

    2016-10-1211,0830 total
    Common Stock (14,716 underlying)
  • Conversion

    Series B Preferred Stock

    2016-10-1220,5830 total
    Common Stock (20,583 underlying)
  • Conversion

    Common Stock

    2016-10-12+49,57049,570 total
  • Conversion

    Series C Preferred Stock

    2016-10-1214,2710 total
    Common Stock (14,271 underlying)
Transactions
  • Conversion

    Common Stock

    2016-10-12+49,57049,570 total
  • Conversion

    Series C Preferred Stock

    2016-10-1214,2710 total
    Common Stock (14,271 underlying)
  • Conversion

    Series B Preferred Stock

    2016-10-1220,5830 total
    Common Stock (20,583 underlying)
  • Conversion

    Series A Preferred Stock

    2016-10-1211,0830 total
    Common Stock (14,716 underlying)
Halak Brian K
10% Owner
Transactions
  • Conversion

    Series A Preferred Stock

    2016-10-1211,0830 total
    Common Stock (14,716 underlying)
  • Conversion

    Common Stock

    2016-10-12+49,57049,570 total
  • Conversion

    Series C Preferred Stock

    2016-10-1214,2710 total
    Common Stock (14,271 underlying)
  • Conversion

    Series B Preferred Stock

    2016-10-1220,5830 total
    Common Stock (20,583 underlying)
TREU JESSE I
10% Owner
Transactions
  • Conversion

    Common Stock

    2016-10-12+49,57049,570 total
  • Conversion

    Series A Preferred Stock

    2016-10-1211,0830 total
    Common Stock (14,716 underlying)
  • Conversion

    Series B Preferred Stock

    2016-10-1220,5830 total
    Common Stock (20,583 underlying)
  • Conversion

    Series C Preferred Stock

    2016-10-1214,2710 total
    Common Stock (14,271 underlying)
BLAIR JAMES C
10% Owner
Transactions
  • Conversion

    Series A Preferred Stock

    2016-10-1211,0830 total
    Common Stock (14,716 underlying)
  • Conversion

    Common Stock

    2016-10-12+49,57049,570 total
  • Conversion

    Series B Preferred Stock

    2016-10-1220,5830 total
    Common Stock (20,583 underlying)
  • Conversion

    Series C Preferred Stock

    2016-10-1214,2710 total
    Common Stock (14,271 underlying)
Footnotes (3)
  • [F1]The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
  • [F2]As managing members of the sole general partner of Domain Partners VII, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own the securities of the Issuer held by Domain Partners VII, L.P., as reported on a Form 4 for Domain Partners VII, L.P. filed on the same date as this Form 4.
  • [F3]All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The preferred stock had no expiration date.

Issuer

OBALON THERAPEUTICS INC

CIK 0001427570

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001427570

Filing Metadata

Form type
4
Filed
Oct 13, 8:00 PM ET
Accepted
Oct 14, 12:04 PM ET
Size
18.7 KB